Researchers from NYU Grossman School of Medicine and NYU’s Laura and Isaac Perlmutter Cancer Center found that amyloid beta, a protein known to build-up in the brains of Alzheimer’s patients, helps melanoma cells thrive when they have spread to the brain. The study authors focused on melanoma because it metastasizes to the brain in 40% of patients with stage IV disease.
A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a phase I clinical trial led by John Zaia, Aaron D. Miller and Edith Miller Chair for Gene Therapy.
Boston Cell Standards has established the Consortium for Analytic Standardization in Immunohistochemistry. The organization is led by an international panel of pathologists and scientists focused on improving patient immunohistochemistry test accuracy and reproducibility.
Cancer Support Community and the Colorectal Cancer Alliance have partnered to expand CSC’s flagship research study, the Cancer Experience Registry.
The Barbara Ann Karmanos Cancer Institute and Lifeguard Health Networks will collaborate to pilot a connected care program that provides patients and caregivers an integrated digital care platform to help them manage cancer care at home.
FDA approved Opdivo (nivolumab) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting.
FDA accepted a supplemental New Drug Application for Tibsovo (ivosidenib tablets) as a potential treatment for patients with previously untreated IDH1-mutated acute myeloid leukemia. The sNDA was granted priority review.
FDA issued three final guidances to industry regarding cancer clinical trials that parallel the goals of President Biden’s recently announced effort to renew and build upon his 2016 Cancer Moonshot initiative to facilitate continued advancement in cancer prevention, detection, research, and patient care (The Cancer Letter, Feb. 4, 2022).
Wednesday, March 8, marks six months since FDA failed to meet its court-ordered deadline to rule on all e-cigarette and other new tobacco product manufacturers’ applications.
The National Cancer Institute approved the following clinical research studies last month.
